ABSTRACT
The 8th GCC Closed Forum for Bioanalysis was held in Baltimore, MD, USA on 5 December 2013, immediately following the 2013 AAPS Workshop (Crystal City V): Quantitative Bioanalytical Methods Validation and Implementation--The 2013 Revised FDA Guidance. This GCC meeting was organized to discuss the contents of the draft revised FDA Guidance on bioanalytical method validation that was published in September 2013 and consolidate the feedback of the GCC members. In attendance were 63 senior-level participants, from seven countries, representing 46 bioanalytical CRO companies/sites. This event represented a unique opportunity for CRO bioanalytical experts to share their opinions and concerns regarding the draft FDA Guidance, and to build unified comments to be provided to the FDA.
Subject(s)
Chemistry Techniques, Analytical/standards , Guidelines as Topic , Validation Studies as Topic , Biomarkers/analysis , Calibration , Ligands , Limit of Detection , Reagent Kits, Diagnostic , Reproducibility of Results , United States , United States Food and Drug AdministrationABSTRACT
The 2014 8th Workshop on Recent Issues in Bioanalysis (8th WRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years' editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for Large molecules bioanalysis using LBA and Immunogenicity. Part 1 (Small molecules bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies' Input) were published in the Bioanalysis issues 6(22) and 6(23), respectively.
Subject(s)
Chemistry Techniques, Analytical , Immunity , Antibodies, Neutralizing/immunology , Biotransformation , Humans , Pharmaceutical Preparations/metabolism , Pharmacokinetics , Polyethylene/chemistry , Practice Guidelines as Topic , United States , United States Food and Drug AdministrationABSTRACT
The topic of incurred sample stability (ISS) has generated considerable discussion within the bioanalytical community in recent years. The subject was an integral part of the seventh annual Workshop on Recent Issues in Bioanalysis (WRIB) held in Long Beach, CA, USA, in April 2013, and at the Global CRO Council for Bioanalysis (GCC) meeting preceding it. Discussion at both events focused on the use of incurred samples for ISS purposes in light of results from a recent GCC survey completed by member companies. This paper reports the consensus resulting from these discussions and serves as a useful reference for depicting ISS issues and concerns, summarizing the GCC survey results and providing helpful recommendations on ISS in the context of bioanalytical method development and application.
Subject(s)
Clinical Chemistry Tests , Data Collection , Reproducibility of ResultsABSTRACT
For biosimilar drug development, it is critical to demonstrate similar physiochemical characteristics, efficacy, and safety of the biosimilar product compared to the reference product. Therefore, pharmacokinetic (PK) and immunogenicity (antidrug antibody, ADA) assays that allow for the demonstration of biosimilarity are critical. Under the auspices of the American Association of Pharmaceutical Scientists (AAPS) Ligand-Binding Assay Bioanalytical Focus Group (LBABFG), a Biosimilars Action Program Committee (APC) was formed in 2011. The goals of this Biosimilars APC were to provide a forum for in-depth discussions on issues surrounding the development and validation of PK and immunogenicity assays in support of biosimilar drug development and to make recommendations thereof. The Biosimilars APC's recommendations for the development and validation of ligand-binding assays (LBAs) to support the PK assessments for biosimilar drug development are presented here. Analytical recommendations for the development and validation of LBAs to support immunogenicity assessments will be the subject of a separate white paper.
Subject(s)
Biological Assay/methods , Biosimilar Pharmaceuticals/pharmacokinetics , Drug Discovery , Practice Guidelines as Topic , Radioligand Assay/methods , Validation Studies as Topic , Biological Assay/standards , Calibration , Ligands , Radioligand Assay/standards , Reference StandardsABSTRACT
The 2013 7th Workshop on Recent Issues in Bioanalysis was held in Long Beach, California, USA, where close to 500 professionals from pharmaceutical and biopharmaceutical companies, CROs and regulatory agencies convened to discuss current topics of interest in bioanalysis. These 'hot' topics, which covered both small and large molecules, were the starting point for fruitful exchanges of knowledge, and sharing of ideas among speakers, panelists and attendees. The discussions led to specific recommendations pertinent to bioanalytical science. Such as the previous editions, this 2013 White Paper addresses important bioanalytical issues and provides practical answers to the topics presented, discussed and agreed upon by the global bioanalytical community attending the 7th Workshop on Recent Issues in Bioanalysis.
Subject(s)
Drug Discovery/methods , Animals , Biochemistry/methods , Biochemistry/standards , Biomarkers, Pharmacological/analysis , California , Chemistry Techniques, Analytical/methods , Chemistry Techniques, Analytical/standards , Drug Approval/methods , Drug Discovery/standards , Humans , Pharmacokinetics , Validation Studies as TopicABSTRACT
The 5th GCC in Barcelona (Spain) and 6th GCC in San Antonio (TX, USA) events provided a unique opportunity for CRO leaders to openly share opinions and perspectives, and to agree upon recommendations on biomarker bioanalytical method validation.
Subject(s)
Biological Assay/standards , Biomarkers/analysis , Calibration , Chromatography, High Pressure Liquid/standards , Contract Services/organization & administration , Humans , Tandem Mass Spectrometry/standards , Validation Studies as TopicABSTRACT
Over 400 professionals representing pharmaceutical companies, CROs, and multiple regulatory agencies participated in the 6th Workshop on Recent Issues in Bioanalysis (WRIB). Like the previous sessions, this event was in the format of a practical, focused, highly interactive and informative workshop aiming for high-quality, improved regulatory compliance and scientific excellence. Numerous 'hot' topics in bioanalysis of both small and large molecules were shared and discussed, leading to consensus and recommendations among panelists and attendees representing the bioanalytical community. The major outcome of this year's workshop was the noticeable alignment of multiple bioanalytical guidance/guidelines from different regulatory agencies. This represents a concrete step forward in the global harmonization of bioanalytical activities. The present 2012 White Paper acts as a practical and useful reference document that provides key information and solutions on several topics and issues in the constantly evolving world of bioanalysis.
Subject(s)
Chromatography, High Pressure Liquid/methods , Guidelines as Topic , Immunoassay/methods , Mass Spectrometry/methods , Pharmaceutical Preparations/analysis , Recombinant Proteins/analysis , Calibration , Chromatography, High Pressure Liquid/standards , Dried Blood Spot Testing/methods , Drug Industry , Government Regulation , Humans , Immunoassay/standards , Mass Spectrometry/standards , Reproducibility of Results , Sensitivity and Specificity , Validation Studies as TopicSubject(s)
Biomarkers/analysis , Biosimilar Pharmaceuticals/analysis , Pharmaceutical Preparations/analysis , Biosimilar Pharmaceuticals/pharmacokinetics , Biosimilar Pharmaceuticals/standards , Chromatography, High Pressure Liquid/standards , Drug Industry , Mass Spectrometry/standards , Pharmaceutical Preparations/standards , Quality Control , Reference StandardsABSTRACT
An open letter written by the Global CRO Council for Bioanalysis (GCC) describing the GCC survey results on stability data from co-administered and co-formulated drugs was sent to multiple regulatory authorities on 14 December 2011. This letter and further discussions at different GCC meetings led to subsequent recommendations on this topic of widespread interest within the bioanalytical community over the past 2 years.
Subject(s)
Drug Combinations , Pharmaceutical Preparations/analysis , Technology, Pharmaceutical/standards , Biomarkers/analysis , Chromatography, High Pressure Liquid/methods , Drug Stability , Government Regulation , Guidelines as Topic , Humans , Tandem Mass Spectrometry/methodsABSTRACT
Imminent patent expiry for a number of biological products currently on the market (many of which are blockbusters) has created an increasing opportunity for the development of biosimilars in the biotechnology industry. The key for successful biosimilar development is to demonstrate biosimilarity to the originator drug. In addition to demonstrating the similarity of physical and chemical properties between biosimilar and originator compounds, regulatory agencies require that immunogenicity be evaluated in comparative studies between biosimilar and originator drugs. Immunogenicity assays are generally non-quantitative (qualitative) and proving similarity/comparability based on qualitative assays can be very challenging. This review will discuss the challenges of developing and validating immunogenicity assays to support preclinical and clinical comparative studies for biosimilar drug development as well as the challenges in association with the interpretation of the data.
Subject(s)
Biosimilar Pharmaceuticals/pharmacology , Drug Discovery/methods , Drug Discovery/standards , Drug Design , Drug Evaluation, Preclinical/methods , Drug Industry , Humans , Immunity/drug effects , Immunogenetic PhenomenaABSTRACT
The 5th Workshop on Recent Issues in Bioanalysis (WRIB) was organized by the Calibration and Validation Group as a 2-day full immersion workshop for pharmaceutical companies, CROs and regulatory agencies to discuss, review, share perspectives, provide potential solutions and agree upon a consistent approach to recent issues in the bioanalysis of both small and large molecules. High quality, better compliance to regulations and scientific excellence are the foundation of this workshop. As in the previous editions of this significant event, recommendations were made and a consensus was reached among panelists and attendees, including industry leaders and regulatory experts representing the global bioanalytical community, on many 'hot' topics in bioanalysis. This 2011 White Paper is based on the conclusions from this workshop, and aims to provide a practical reference guide on those topics.
Subject(s)
Pharmaceutical Preparations/analysis , Calibration , Chromatography, High Pressure Liquid/methods , Chromatography, High Pressure Liquid/standards , Dried Blood Spot Testing/methods , Dried Blood Spot Testing/standards , Drug Industry , Government Regulation , Guidelines as Topic , Humans , Mass Spectrometry/instrumentation , Mass Spectrometry/methods , Mass Spectrometry/standards , Technology Transfer , Tissue Array Analysis/methods , Tissue Array Analysis/standards , Validation Studies as TopicABSTRACT
With the imminent expiry of patents on a number of biological products on the market, the development of biosimilars (or 'follow-on biologics') creates an increasing opportunity in the biotechnology industry. Although general guidelines on the quality and safety of biological products also apply to biosimilars, there is a need to address specific requirements for developing biosimilar drugs. Since it is critical to show comparability of the biosimilar products to their reference (or innovator) products, developing the appropriate bioanalytical methods to support such preclinical and clinical comparability studies is of great importance. The present work recommends the requirements for the development and validation for both pharmacokinetic and immunogenicity assays to support the biosimilar drug development.
Subject(s)
Biological Products/standards , Biological Products/therapeutic use , Drug Industry/standards , Drugs, Generic/pharmacology , Drugs, Generic/standards , Animals , Biological Products/adverse effects , Biological Products/pharmacology , Drugs, Generic/adverse effects , Drugs, Generic/pharmacokinetics , Guidelines as Topic , Humans , Immunity/drug effectsABSTRACT
Covalent attachment of polyethylene glycol, PEGylation, has been shown to prolong the half-life and enhance the pharmacodynamics of therapeutic proteins. Current methods for PEGylation, which rely on chemical conjugation through reactive groups on amino acids, often generate isoforms in which PEG is attached at sites that interfere with bioactivity. Here, we present a novel strategy for site-directed PEGylation using glycosyltransferases to attach PEG to O-glycans. The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues. The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.